Ani Pharmaceuticals (ANIP) Capital Expenditures (2010 - 2026)

Ani Pharmaceuticals has disclosed Capital Expenditures across 17 years of filings, most recently posting $6.1 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $6.1 million, up 145.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.4 million (changed 0.3% YoY), and the FY2025 annual result was $13.8 million, down 14.79% from the prior year.
• Capital Expenditures came in at $6.1 million for Q1 2026 at Ani Pharmaceuticals, up from $1.2 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $15.6 million in Q4 2024 to a low of -$8.4 million in Q3 2024.
• The 5-year median for Capital Expenditures is $1.2 million (2025), against an average of $2.7 million.
• Peak annual rise in Capital Expenditures reached 19160.49% in 2024, while the deepest fall reached 2775.0% in 2024.
• Ani Pharmaceuticals' Capital Expenditures stood at $3.1 million in 2022, then plunged by 97.42% to $81000.0 in 2023, then surged by 19160.49% to $15.6 million in 2024, then slumped by 92.03% to $1.2 million in 2025, then jumped by 388.26% to $6.1 million in 2026.
• The last three Capital Expenditures figures came in at $6.1 million (Q1 2026), $1.2 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.